Fibromun (L19-TNF) is a fully-human immunomodulatory product, currently being tested in clinical trials in patients with cancer. It consists of the anti-EDB human antibody L19, fused to human TNF, a strong pro-inflammatory cytokine. Recombinant TNF (Beromun®, Boehringer Ingelheim) has so far been approved only for certain clinical applications.

Fibromun has previously been studied in clinical trials in Melanoma in the Isolated Limb-Perfusion setting and in a systemic clinical trial.

  • Two pivotal clinical trials for Fibromun in combination with doxorubicin in metastatic Soft Tissue Sarcoma are ongoing in Europe and in the USA.
  • A Phase II clinical trial with Fibromun in combination with dacarbazine in pretreated Soft Tissue Sarcoma is planned to start in 2020.


Hemmerle and Neri (2013) Br. J. Cancer 109 (5) 1206-13;
Papadia et al. (2013) J Surg Oncol., 107, 173-179;
Spitaleri et al (2013) J Cancer Res. Clin. Onc., 139, 447-455;
Balza et al. (2010) Int. J. Cancer, 127 (1) 101-10;
Balza et al. (2006) Clin. Cancer Res., 12, 2575-2582;
Borsi et al. (2003) Blood, 102, 4384-4392;
Halin et al (2003) Cancer Res., 63 (12) 3202-10.

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all of the cookies, please refer to the cookie policy. By closing this banner, scrolling this page, clicking a link or continuing to browse otherwise, you agree to the use of cookies.

I Accept Cookie Policy